Avalo Therapeutics Q2 2023 Earnings Report

Avalo Therapeutics EPS Results

• Actual EPS: -$141.60
• Consensus EPS: -$216.00
• Beat/Miss: Beat by +$74.40
• One Year Ago EPS: N/A

Avalo Therapeutics Revenue Results

• Actual Revenue: $0.64 million
• Expected Revenue: $1.00 million
• Beat/Miss: Missed by -$360.00 thousand
• YoY Revenue Growth: N/A

Avalo Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/3/2023
• Time: N/A
• Conference Call Date: Wednesday, August 2, 2023
• Conference Call Time: 6:00PM ET

Avalo Therapeutics (NASDAQ:AVTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for endocrine disorders and oncology. The company’s pipeline features orally administered molecules designed to modulate hormone pathways and immune responses, aiming to address conditions such as polycystic ovary syndrome, hypogonadism and select solid tumors. Leveraging a platform that integrates small-molecule chemistry and biomarker-driven patient selection, Avalo seeks to deliver targeted treatments with favorable safety and efficacy profiles.

Since its founding in 2015, Avalo has advanced several candidates through preclinical and early clinical studies, forging collaborations with leading academic institutions and contract research organizations. The company’s lead programs are supported by translational science that identifies mechanism-based biomarkers, enabling streamlined clinical development and potential for accelerated regulatory pathways. In addition to its own assets, Avalo maintains strategic partnerships to co-develop or out-license select programs in regions outside North America.

Headquartered in Cambridge, Massachusetts, Avalo maintains research and development facilities in both the United States and Europe to support global clinical trials and regulatory interactions. The company’s management team brings together seasoned executives from major pharmaceutical and biotechnology firms, with collective expertise spanning drug discovery, clinical development and commercial strategy. This leadership team is committed to advancing multiple therapeutic candidates toward later-stage evaluation.

As Avalo pursues the next phase of growth, the company remains focused on leveraging its proprietary platform and collaborative network to address unmet medical needs in hormone-driven diseases and cancer. By combining precision medicine principles with a streamlined development approach, Avalo aims to build a diversified portfolio of differentiated therapies for patients worldwide.